AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03567018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
Study NCT01234584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPK Abutments
Description: implants using CPK Abutments
Study NCT01884571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 20 mg, IV (in the vein) on day 1 and 4.
Study NCT01884571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 125 mg, IV (in the vein) on day 1.
Study NCT04190004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Study NCT04190004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Study NCT03973905 — intervention group
Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis
Study NCT02048033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular endoscopy + endogastric suturing
Description: Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
Study NCT02048033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Regular endoscopy
Description: Patients will get the usual endoscopy used for diagnosis.
Study NCT01628003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Brain MRI
Study NCT01628003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI
Study NCT01628003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Physical examination Neuropsychological testing Questionnaires
Study NCT01628003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Physical examination Neuropsychological testing Questionnaires
Study NCT01884571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
Study NCT01884571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 1-5 mg PO, twice a day (BID) days 2-180.
Study NCT01884571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
Study NCT01078051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher, xience, Endeavor, Taxus
Description: all species of drug-eluting stent implantation
Study NCT00763945 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
Study NCT01078051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal medical therapy
Description: optimal medical therapy
Study NCT02301286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Study NCT02698904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation Technique
Study NCT02698904 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Documentary Movie
Study NCT02137187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV junction ablation
Description: AV junction ablation
Study NCT02137187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
Study NCT02137187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized drug therapy
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control
Study NCT02301286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acetylsalicylic acid
Study NCT02137187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized drug therapy
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control
Study NCT02137187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD
Description: Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
Study NCT02137187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
Study NCT00842101 — intervention group
Intervention type: DEVICE
Intervention: Quick Pressure Monitor
Description: The monitor measures actively the actual pressure inside the compartment affected.
Study NCT02803996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol
Description: Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
Study NCT02803996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
Study NCT03445221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV Immunonutrition
Description: patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
Study NCT03445221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: patients will continue preoperative oral conventional diet.
Study NCT02126007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and Rhythm Intervention
Study NCT02126007 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Modifications
Study NCT03610776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portion control plate
Description: Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
Study NCT03610776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional plate
Description: Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
Study NCT02435706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless immediate implant placement
Description: Experimental group: No elevation of flap prior to immediate implant placement
Study NCT02435706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap assisted immediate implant placement
Description: Control group: Flap will be elevated prior to immediate implant placement
Study NCT02435706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant and temporary crown
Description: Both groups receive this intervention
Study NCT02435706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant and temporary crown
Description: Both groups receive this intervention
Study NCT03930992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colaren in HIV positive
Description: 1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Study NCT03930992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment in HIV positive
Description: 2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Study NCT03930992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colaren in HIV negative
Description: 3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Study NCT03930992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment in HIV negative
Description: 4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Study NCT02068417 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: shock waves
Description: extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
Study NCT02068417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock waves
Description: extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
Study NCT04556422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 15 minutes of aerobic exercise using stationary bicycle
Study NCT04556422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna bathing
Description: Passive heat exposure
Study NCT04556422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sauna bathing
Description: Passive heat exposure
Study NCT02694952 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FAV-Africa
Description: Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
Study NCT02694952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EchiTabPlus-ICP
Description: Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
Study NCT02772900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot-based nutritional gel
Description: 100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
Study NCT04835025 — intervention group
Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitor
Description: In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
Study NCT02507583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
Study NCT02323230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
Study NCT02323230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose cyclophosphamide will be taken by mouth
Study NCT01978587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Study NCT04273646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
Study NCT04273646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
Study NCT02772900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
Study NCT00024011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00024011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00464659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Description: Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
Study NCT00464659 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
Study NCT03459053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBART
Description: Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
Study NCT04356079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: International Headache Society Test
Description: Thorough History of Patients and families
Study NCT05919303 — intervention group
Intervention type: RADIATION
Intervention: CT Scan
Description: CT scan study of abdomen
Study NCT02786147 — intervention group
Intervention type: OTHER
Intervention: Breast Cancer Genetics Referral Screening Tool 3.0
Description: The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0).
Study NCT02786147 — intervention group
Intervention type: OTHER
Intervention: Standard Handout
Description: A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
Study NCT02786147 — intervention group
Intervention type: OTHER
Intervention: Physician Notification
Description: Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
Study NCT02786147 — intervention group
Intervention type: OTHER
Intervention: Automatic Follow-Up by Genetic Counseling Staff
Description: Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
Study NCT01930851 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass operation
Study NCT01986855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
Study NCT01986855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 5 mg
Description: Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
Study NCT01986855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study NCT01986855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 10 mg
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study NCT01986855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10 mg
Description: Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
Study NCT01221532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHHE Peridischarge Intervention
Description: Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care.
Study NCT03745937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
Study NCT03745937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
Study NCT02659709 — intervention group
Intervention type: DEVICE
Intervention: Interest in medical education through social media
Description: Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
Study NCT02428881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
Study NCT04571775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Qi-Shield user group
Description: real device Qi-Shield (treatment)
Study NCT01045057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puncture Set and Flexible Protector
Description: The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
Study NCT04139486 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined EMBOTRAP II or III and Contact Aspiration
Description: refer to title
Study NCT04139486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Aspiration alone
Description: refer to title
Study NCT04246723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
Study NCT02409407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol , Prostaglandins E1 analogue
Study NCT00598234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
Study NCT00598234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
Study NCT04571775 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Qi-Shield user group
Description: sham device (placebo)
Study NCT00424502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1g iv on days 1 and 15
Study NCT00424502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg po/week
Study NCT02680028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: targon pft nail
Description: 220 mm vs 175mm nail
Study NCT02680028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: targon pft nail
Description: 220 mm vs 175mm nail
Study NCT00213759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.